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Tight junction functionThe intestinal epithelium functions to effectively restrict the causal uptake of luminal contents but has been
demonstrated to transiently increase paracellular permeability properties to provide an additional entry route
for dietary macromolecules. We have examined a method to emulate this endogenous mechanism as a means
of enhancing the oral uptake of insulin. Two sets of stable Permeant Inhibitor of Phosphatase (PIP) peptides
were rationally designed to stimulate phosphorylation of intracellular epithelial myosin light chain (MLC) and
screened using Caco-2 monolayers in vitro. Apical application of PIP peptide 640, designed to disrupt protein–
protein interactions between protein phosphatase 1 (PP1) and its regulator CPI-17, resulted in a reversible and
non-toxic transient reduction in Caco-2 monolayer trans-epithelial electric resistance (TEER) and opening of
the paracellular route to 4 kDa ﬂuorescent dextran but not 70 kDa dextran in vitro. Apical application of PIP
peptide 250, designed to impede MYPT1-mediated regulation of PP1, also decreased TEER in a reversible and
non-toxicmanner but transiently opened the paracellular route to both 4 and 70 kDa ﬂuorescent dextrans. Direct
injection of PIP peptides 640 or 250with human insulin into the lumen of rat jejunum caused a decrease in blood
glucose levels that was PIP peptide and insulin dose-dependent and correlated with increased pMLC levels.
Systemic levels of insulin suggested approximately 3–4% of the dose injected into the intestinal lumen was
absorbed, relative to a subcutaneous injection. Measurement of insulin levels in the portal vein showed a time
window of absorption that was consistent with systemic concentration-time proﬁles and approximately 50%
ﬁrst-pass clearance by the liver. Monitoring the uptake of a ﬂuorescent form of insulin suggested its uptake
occurred via the paracellular route. Together, these studies add validation to the presence of an endogenous
mechanism used by the intestinal epithelium to dynamically regulate its paracellular permeability properties
and better deﬁne the potential to enhance the oral delivery of biopharmaceuticals via a transient regulation of
an endogenous mechanism controlling the intestinal paracellular barrier.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Oral peptide delivery has been a goal for the pharmaceutical indus-
try for decades; soon after the identiﬁcation of insulin as a treatment-diamidino-2-phenylindole; FD,
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ersity, Singleton Park, SA2 8PP,
. This is an open access article underfor diabetes, efforts were made to attempt its therapeutic administra-
tion following oral delivery [1]. A physiological rationale exists for this
strategy in the case of certain biopharmaceuticals, such as insulin, as
oral uptake would result in direct delivery to the liver via the portal
circulation, with the liver being the primary site of glucose regulation
in the body [2]. Paramount to successfully achieving this goal is the
sufﬁcient stabilization of labile biopharmaceuticals following oral
administration as they encounter the harsh environment of the stomach
and enzymatic milieu of the small intestine. Protection during gastric
transit can be achieved by enteric coating of the dosage form and agents
generally regarded as safe [3] can be used to suppress peptidase activi-
ties in the small intestine [4]. Despite these efforts, only extremely low
amounts of insulin are observed to transport across intestinal epithelia
[5]. Thus, it is not surprising that a plethora of efforts have been
described to enhance the transport rate of a biopharmaceutical by
disrupting or disorganizing the tight junction (TJ) structures that re-
strict the ﬂux of macromolecules between adjacent epithelial cells [6,7].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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TJ structures through the reversible phosphorylation of a 20 kDa regula-
tory myosin light chain (MLC) protein; the set position for MLC is
de-phosphorylated to keep TJs in a ‘closed’ state [8]. Closed TJs limit
the paracellular uptake of hydrophilic agents with a size greater than
b15 Å, which equates to a molecular mass of ~3.5 kDa [9]. Transient TJ
“opening” to enhance paracellular nutrient uptake, however, has been
suggested as a natural phenomenon of intestinal physiology [10] and
increased levels of phosphorylated MLC are associated with open TJs
[11]. Since MLC phosphorylation is dynamically regulated in polarized
epithelial cells by a speciﬁc kinase (MLCK) and a speciﬁc phosphatase
(MLCP), we have examinedmethods to selectively blockMLCP function
as a means to transiently increase MLC phosphorylation by basal MLCK
activity. The role of MLC phosphorylation in regulating TJ paracellular
permeability properties was previously validated using a D-amino
acid,membrane-permeable peptide, termed PIK that selectively inhibits
active MLCK activity [12–14].
MLCP is a trimeric complex consisting of a protein phosphatase-1
(PP1) isoform, the myosin targeting subunit MYPT1-CPI-17 regulatory
complex, and a 21 kDa accessory subunit [15–17]. We examined the
potential for rationally designed small peptides that emulate speciﬁc
MLCP holoenzyme domains involved in protein–protein interfacial
contacts to regulate its catalytic activity and thereby affect TJ-mediated
barrier function. To identify potential Permeant Inhibitor of Phospha-
tase (PIP) peptides, we focused on interactions between MYPT1 or
CPI-17 with PP1. We assumed that differences in MLCP regulation by
Rho kinase versus protein kinase C (PKC) pathway activation would
be recapitulated by PIP peptides that disrupted interactions between
PP1 and MYPT1 or CPI-17, respectively. Thus, the effectiveness and
duration of action of such PIP peptides should be dependent upon
several factors: their biochemical stability, access to cytoplasmic MLCP
in intestinal epithelial cells, residence time at speciﬁc protein–protein
interfacial surfaces, and the role of that protein–protein interaction in
MLCP function. We now report the identiﬁcation two rationally
designed PIP peptides that are capable of dynamically opening TJs
in vitro and that enhance the uptake of biologically active insulin
in vivo. These results further reﬁne our understanding of how speciﬁc
protein–protein interactions within the MLCP holoenzyme may regu-
late its functional properties in intestinal epithelial cells.
2. Materials and methods
2.1. Peptide synthesis
Peptides were synthesized by (Fmoc)-SPPS using amino acid deriv-
atives obtained from Novabiochem, except for isoleucine, which was
obtained from Sigma Aldrich. The ﬁrst amino acid was coupled to Rink
Amide MBHA resin (100–200 mesh; Novabiochem) using N,N′-diiso-
propylcarbodiimide and 1-hydroxbenzotriazole [18]. Subsequent
couplings were carried out on an Activo P-11 peptide synthesizer
using PyBOP. Deprotection was carried out using 20% piperidine in
dimethylformamide. Peptides were cleaved from the resin using
triﬂuoroacetic acid (TFA), triisopropylsilane and water (95:2.5:2.5)
[19], and precipitated in diethyl ether. Crude product was puriﬁed by
HPLC, using a Phenomenex Gemini C18 column (250 × 10 mm, pore
size 5 μm) and a gradient mobile phase of water and acetonitrile (both
with 0.1% TFA) using a ﬂow rate of 2.5 mL/min. High-resolution time-
of-ﬂight mass spectra were obtained on a Bruker Daltonics micrOTOF
mass spectrometer using electrospray ionization (ESI) to verify peptide
identity. Puriﬁed peptides were lyophilized and stored at−20 °C.
2.2. Cell culture
An immortalized human intestinal epithelial cell line (Caco-2) was
maintained in DMEM/F12 (Gibco, Paisley, UK) supplemented with 10%
FBS, 2 mM L-glutamine (Gibco) 100U/mL penicillin and 100 μg/mLstreptomycin (Gibco). Caco-2 cells were seeded at a density of
7 × 104/well on Transwell™ (Corning, NY) polyester membrane ﬁlters
(12 mm diameter, 0.4 μm pore size). Feeding with fresh media (Life
Technologies, Paisley, UK) was carried out every second day [20].
Caco-2 monolayers with trans-epithelial electrical resistance (TEER)
N350 Ω·cm2, as measured using ﬁxed paddle electrodes and a
voltohmeter (World Precision Instruments©, UK) that was typically
achieved between days 15–18 following seeding on Transwell™ ﬁlters
were used for these studies.
2.3. In vitro transport studies
Apical to basal ﬂux of 50 mg/ml 4 kDa dextran or 50 mg/mL 70 kDa
dextran (Sigma) was performed to assess the impact of PIP peptides on
paracellular permeability [21]. Apical (200 μL) and basal (600 μL) com-
partmentmediawere replacedwithHBSS and allowed to equilibrate for
30 min; TEER measurements were obtained prior to use to ensure
monolayer integrity [22]. After apical application of the dextrans the
basal compartment volume was collected at set times (typically 0, 15,
30 60, 90, and 180 min) and replaced with fresh HBSS. Apical and
basal compartment ﬂuorescence was determined using a Fluorostar
Omega microplate reader (BMG Labtech, Ortenburg, Germany). After
3 h, the apical compartment dextran and peptide solutionwas removed
and replaced with PBS and TEER values were recorded for a further
30 min to assess monolayer recovery. TEER values were calculated by
subtracting blank ﬁlter readings and normalized as a percentage of the
initial TEER value for that monolayer [20].
2.4. In vivo studies
Male Wistar rats were housed in groups of 3–5 per cage with a 12/
12 h light/dark cycle and weighed 225–275 g (approximately 6–
8 weeks old) when placed on study. All experiments were conducted
during the light phase with animals having ad lib access to food and
were carried out using a non-recovery protocol that used continuous
isoﬂurane anesthesia. Inhaled isoﬂurane was used instead of other
forms of anesthesia that can affect blood glucose levels [23,24]. A 4–
5 cm midline abdominal incision was made to expose the small intes-
tine (mid-jejunum to proximal ileum regions) and to provide access
to the portal vein for blood collection. Stock solutions of insulin
(human recombinant; Sigma) and PIP peptides were prepared in phos-
phate buffered saline (PBS) containing 10mM citric acid (pH 4.5) to re-
duce local proteolysis [4] and mixed 1:1 before injection using a 29-
gauge hypodermic needle in a volume of 200 μL/kg (or ~50 μL per
250 g rat). The injection site mesentery was marked with a permanent
marker. Blood drawswere taken from the portal vein aswell as systemic
circulation over the next 2 h to measure glucose using a glucometer
(AccuChek), serum insulin by ELISA (EMD Millipore Corp.), and endo-
toxin by Limulus Amebocyte Lystae (LAL) chromogenic assay (Thermo
Scientiﬁc). Control treatment groups included intestinal injection of
PIP peptide without insulin or insulin alone. At study termination, a 3–
5 mm region that captured the marked intestine segment was isolated.
This tissue was lysed for biochemical assessment or ﬁxed, sectioned,
and stained with hematoxylin/eosin prior to analysis read by KWS
BioTest, a licensed veterinary pathologist. Subcutaneous (SC) insulin in-
jections (20 μL/kg) were performed in the mid-scapular region with
blood glucose and venous insulin levels being as above. All experiments
were performed in accordance with the U.K. Animals (Scientiﬁc Proce-
dures) Act of 1986, the European Communities Council Directive of
1986 (86/609/EEC), and the University of Bath's ethical review
procedures.
2.5. PhosphoMLC analysis
After rinsing with ice cold PBS to remove PIP peptide or control
treatment agents, isolated intestinal tissue was placed in ice cold PBS
Table 1
CPI-17 derived peptides tested *.
No. Peptide sequence Efﬁcacy
600 NH2-RRVTVKYDRR-NH2 No
605 NH2-RRVpTVKYDRR-NH2 No
610 NH2-RRVTVKYKRR-NH2 No
615 NH2-RRVpTVKYKRR-NH2 No
620 NH2-RRKTVKYDRR-NH2 No
630 NH2-RRVEVKYDRR-NH2 Yes
*R36VTVKYDRR44 was selected as the starting sequence (peptide 600). Residues were var-
ied in test series as indicated (bold, underlined). Efﬁcacy was determined by TEER reduc-
tion following apical application of 5 mM to Caco-2 cell monolayers with a two-fold
increase in 4 kDa dextran ﬂux as the efﬁcacy threshold. Peptide 630 (NH2-
RRVEVKYDRR-NH2) was synthesized in the retro-inverso form with D-amino acids as
PIP peptide 640 (NH2-rrdykvevrr-NH2).
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25 μL phosphatase inhibitor cocktail (Fisher) and 500 μL RIPA buffer
(Sigma Aldrich). After 10 min on ice, lysates were centrifuged at
8000 rpm for 15 min to collect the supernatant, which was stored
at−80 °C until use. For Western blot analysis, lysates were separated
by SDS-PAGE (12%) run at 220 V for 40 min and electro-transferred
onto a PDVFmembrane at 30 V for 70min using an XCell™ Blot module
(Invitrogen). Membranes were blocked using 5% bovine serum albumin
in TBS-T (2 M Tris HCl, pH 7.5, 4 M NaCl and 0.1% Tween 20) for 1 h.
Membraneswerewashedwithwater, incubatedwith primary antibody
(anti-myosin light chain (phospho S19) antibody (Cell Signaling Tech-
nologies)) or anti-myosin light chain 2 antibody (Abcam) overnight at
5 °C, washed thrice with TBS-T, and then incubated with secondary
horseradish peroxide (HRP)-coupled antibody for 1 h at room tempera-
ture. After washing thrice in TBS-T, HRP activity was detected by ECL
(Santa Cruz).
2.6. Cell viability measurement
Induction of apoptosis, as a measure of early stage cell intoxication,
was assessed by examining caspase-3 enzyme activity using the
APT165 commercial kit as per manufacturer's instructions (Millipore,
Watford, UK). Intestinal tissues were isolated 45 min after exposure to
test agents administered by direct intestinal intraluminal injection.
Hygromycin (150 μg/mL) was administered as a positive control to
incite apoptosis through caspase-3 activation [25].
2.6.1. Microscopy
PIP peptide-mediated uptake of Cy3-labeled insulin (Nanocs) was
evaluated in vivo where exposed intestinal segments were isolated
15 min after administration for microscopic analysis. Isolated tissues
were rinsed brieﬂy in ice-cold PBS and then ﬁxed with 4% paraformalde-
hyde on ice prior to assessment using a Zeiss LSM510ﬂuorescencemicro-
scope. DAPI (4′,6-diamidino-2-phenylindole) was used as a nuclear stain.
2.6.2. Data analysis
Statistical analysis was performed using GraphPad Prism 4.0 soft-
ware. Data comparisons for dextran transport, Western blot intensity
and caspase-3 activity were performed using a two-tailed, un-paired
Student's T-test. A p-value of b0.05 was considered signiﬁcant. Data
comparisons for TEER, blood glucose and blood insulin were performed
using a one-way ANOVA. Where the ANOVA showed a signiﬁcant
variance between data sets, a Bonferroni post-test was performed to
compare PIP peptide data sets to the control data set. A p-value of
b0.05 was considered signiﬁcant.
3. Results
3.1. PIP peptide design
3.1.1. Targeting PP1-CPI-17 interactions
Inhibition of MLCP by CPI-17 is driven by PKC-stimulated events
with the phosphorylation of residue T38 (pT38) in CPI-17 enhancing
MLCP inhibition over 1000-fold [26]. To target this PP1-CPI-17 interac-
tion, we examined the known structural information (PBD ID: 2RLT)
and designed a small cadre of peptides emulating the R36VTVKYDRR44
sequence in CPI-17 that interacts with PP1 (Table 1). These peptides
were synthesized with T38 as a focal point due to its phosphorylation
potential [15]. Glutamic acid (E) was used to mimic pT38; additional
basic amino acids were introduced to emulate cell penetrating peptide
(CPP) sequences to enhance membrane permeability [27,28] and all
D-amino acids in the reverse orientation were used to increase stability
[29]. A lead candidate, peptide 640 = rrdykvevrrkkr-NH2, was
identiﬁed.3.1.2. Targeting PP1-MYPT1 interactions
MLCP inhibition occurs following phosphorylation of residues T696
and T853 in MYPT1 mediated by Rho-kinase [16,17,30]. MYPT1 binds
PP1 via 3 different regions: the RVxF binding motif, the N-terminal
arm and the 2nd group of ankyrin repeats of this protein. While phos-
phorylation of MYPT1 at both T696 and T853 appears be involved in
MLCP regulation, a KVKF sequence within the 300 residue N-terminal
domain of MYPT1 facilitates its association with PP1. Analysis of
published crystal structures shows that E300 to E309 of PP1 is positioned
between 2 ankyrin repeats of MYPT; in particular the ankyrin repeats
bind with Y305 and Y307, suggesting that the C terminus of PP1 is impor-
tant for regulatory subunit interaction to mediate isoform speciﬁcity.
We therefore speculated that a peptide corresponding to the MYPT1
binding motif could prevent MYPT binding to PP1 and hence diminish
myosin speciﬁcity of the MYPT/PP1 complex. To test this hypothesis
we used a strategy similar to that described above for peptide 640 to
identify an all D-amino acid peptide referred to as 250: rrfkvktkkrk-NH2.3.2. In vitro studies
In order to adequately compare PIP 250 and 640, we attempted to
match the two peptides based on response changes in TEER [22]. This
was done because of several uncertainties that make a direct dose
comparison inappropriate since it is likely that the two peptides have
different properties critical to their actions: accessibility to their intra-
cellular targets (due to differing CPP capabilities), binding afﬁnities for
their respective MLCP-related targets, off-target actions, and intracellu-
lar stabilities. We determined that an apical application of 20 mM
peptide 250 and 10 mM peptide 640 provided comparable responses
as evidenced by changes in TEER (Fig. 1). Reducing the apical dose of
these two PIP peptides resulted in dose-dependent changes in TEER
with regard to both time of onset and maximum effect. After 180 min
of PIP peptide exposure, apical compartment replacement with fresh
media initiated reversal of TEER depression that was more rapid for
cells exposed to peptide 640 compared to peptide 250. Under all condi-
tions, complete TEER recovery was achieved by 24 h. Similar peptides,
with amino acid sequences distinct from PIP peptides 250 and 640,
failed to affect Caco-2 monolayer TEER values when tested at 20 mM
(data not shown).
We next asked if the actions of PIP peptides 640 and 250 on TEER
values translated to changes in paracellular permeability by monitoring
the cumulative apical to basal transport of ﬂuorescent dextrans (Fig. 2).
Despite producing a nearly 50% loss in TEER after 180 min of exposure,
5 mM of peptide 640 failed to affect 4 kDa dextran permeability. Apical
application of 10 mM peptide 640 increased the rate of 4 kDa perme-
ation by ~3-fold. Interestingly, 10 mM peptide 640 was equal to
10 mM peptide 250 with regard to 4 kDa ﬂux rates; despite having a
slightly delayed and less intense impact on TEER changes. Strikingly,
20 mM peptide 250 resulted in twice the ﬂux rate (~6-fold compare
to control) for 4 kDa dextran compared to 10 mM peptide 640 even
Fig. 1. PIP peptides can reversibly affect the trans-epithelial electrical resistance (TEER)
properties across conﬂuent, polarized monolayers of Caco-2 cells in vitro. Changes in per-
centage (%) of initial TEER values measured over time following apical application of PIP
peptide 250 or peptide 640 at designated concentrations demonstrated concentration-
and time-dependent action. Arrow represents time point when the PIP peptide in the api-
cal compartmentwas replacedwith PBS (washout). Control iswhere PBSwas added to the
apical surface with no peptide. Data are means ± SD, n = 6 for control and n = 5 for all
peptide groups. One-way ANOVA showed that the data sets were signiﬁcantly different
from each other (p b 0.0001). Bonferroni post-tests showed that 10 mM peptide 250
(p b 0.01), 20 mM peptide 250 (p b 0.001) and 10 mM peptide 640 (p b 0.001) were sig-
niﬁcantly different from control.
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ments. We also observed that peptide 640 failed to affect the ﬂux of
70 kDa dextran while peptide 250, at 20 mM, could increase this ﬂux
~3-fold. The linearity of 4 kDa dextran ﬂux enhancement suggested
that permeability changes induced by these PIP peptides was quite
rapid despite the time required to achieve a plateau of TEER response
(Fig. 1). There was, however, the suggestion of a slightly delayed induc-
tion of enhanced 70 kDa dextran transport induced by 20 mM peptide
250. Overall, these results suggest that peptide 640 may induce aFig. 2. PIP peptide 250 can enhance the uptake of larger solutes than peptide 640 in vitro.
Cumulative apical to basal transport of ﬂuorescent dextran across Caco-2 monolayers in-
duced by the apical application of designated concentrations of PIP peptide 250 or 640.
(A) 4 kDa dextran transport induced by peptides 250 and 640. (B) 70 kDa dextran trans-
port induced by peptides 250 and 640. PBS added to the apical compartment served as
control. Data aremeans±SD, n=6 for control andn=5 for all peptide treatment groups.
* Signiﬁcantly different from control with two-tailed, un-paired t-test.more rapid onset but less robust and durable opening of the paracellular
route compared to equivalent actions (based upon TEER) induced by
peptide 250.
3.3. In vivo supression of blood sugar by insulin
Our focus was to examine intestinal epithelial transport prior to
addressing formulation challenges related to bypassing stomach acids
and pancreatic enzymes; such challenges can be solvedwith established
pill or tablet technologies but require higher order animal models for
adequate evaluation. Presently, we used a rat model where a small
(50 μL) volume was directly injected into lumen of distal jejunum and
proximal ileum segments. It is important to note that the protein–pro-
tein interfacial domains being targeted by these PIP peptides are highly
conserved between human and rat. We wished to test PIP peptides 250
and 640 at concentrations derived from our in vitro Caco-2 studies and
calibrated their actions via intraluminal intestinal injection (ILI) in vivo.
Human insulin was selected; it has rapid and easily measured pharma-
codynamics (PD) and can be discriminated from endogenous rat insulin
by ELISA to derive pharmacokinetic (PK) information. SubcutaneousFig. 3. PIP peptides administeredwith human insulin can suppress serumglucose levels in
non-diabetic rats in vivo. (A) SC injection of human insulin resulted in a dose-dependent,
reversible suppression of systemic blood glucose levels. Systemic blood glucose levels over
time following ILI injection of 30 IU/kg human insulin alone or with (B) peptide 250 or
(C) peptide 640. Controls included ILI injection of PIP peptides alone. 10 mM peptide
250 + insulin (p b 0.001), 20 mM peptide 250 + insulin (p b 0.001) and 20 mM peptide
640 + insulin (p b 0.01) were signiﬁcantly different from insulin only.
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dependent and reversible decline in peripheral blood glucose
(Fig. 3A). Insulin injected at 3 IU/kg produced ~50% decrease in blood
glucose, from 10.1 mM to 4.7 mM, that reached its nadir by ~30 min
and began to recover by ~60 min (Fig. 3A); 1 IU/kg insulin reduced
blood glucose from 10.3 mM to 7.9 mM, or ~75% of baseline, after
30 min with recovery beginning soon after.
ILI injection of 30 IU/kg insulin had no effect on blood sugar (Fig. 3B),
however the sameamount of insulin plus 10mMPIP peptide 250 result-
ed in a blood glucose drop and recovery proﬁle similar to that observed
for the SC injection of 3 IU/kg of insulin (Fig. 3B). PIP peptide 250 dosed
at 10 mM with 30 IU/kg insulin reduced blood glucose levels from
10.9 mM to 5.7 mM by 50 min, a drop to 50% of initial blood glucose.
PIP peptide 250 dosed at 20 mM with 30 IU/kg insulin reduced blood
glucose levels from 14.8 mM to 8.8 mM by 40 min, which was a drop
to 60% of initial blood glucose. While recovery to 70–80% of the initial
blood sugar level was achieved by 90 min following 10 mM PIP peptide
250 dosing with 30 IU/kg, 20 mM peptide 250 administered with
30 IU/kg by ILI injection resulted in a greater drop in blood glucose by
30min that remained at this level for the remainder of the 90min exper-
iment. ILI injection of 30 IU/kg of insulin with 10mMpeptide 640 result-
ed in a more delayed decrease in blood glucose (Fig. 3C) relative to SC
injection (Fig. 3A) or 10 mM peptide 250 (Fig. 3B). ILI injection of
30 IU/kg insulin alone or 20mM of either peptide 250 or 640without in-
sulin failed to affect blood sugar levels (Fig. 3B & C).
PIP peptide 640 dosed at 10 mM with 30 IU/kg insulin resulted in
reduced blood glucose levels after 60 min, dropping from 10.0 mM to
6.3 mM by 70 min; a decrease to 62.5% of baseline. PIP peptide 640
dosed at 20 mM with 30 IU/kg insulin reduced blood glucose levels
after 30 min, dropping from 10.9 mM to 5.2 mM after 50 min; a
decrease to 48% of baseline. Blood glucose levels began to return to
basal levels by 60 min after ILI injection of peptide 640 tested under
these conditions. Thus, ILI injection of 20 mM peptide 640 was required
to produce a similar effect and recovery proﬁle as that observed with
10 mM peptide 250 in this in vivo model, but the response appeared
to be more dynamic.
3.4. Mechansim of PIP peptide actions
These in vivo results are, in general, consistent with our in vitro
studies performed using the human intestinal epithelial cell line Caco-2
that suggested a dynamic alteration in paracellular permeability (Figs. 1
& 2). As anticipated, the actions of these PIP peptides in vivo were
transient and the duration and time onset of their actions was dose-
dependent. Differences between PIP peptides 250 and 640 were readily
apparent in vitro where their absolute concentration and duration of ex-
posure could be controlled. We examined the onset and duration of PIP
peptides 250 and 640 actions in vivo by determining the phosphorylation
status ofMLC by comparing the extent of phosphoserine at position 19 of
MLC (pMLC) to total MLC in rat intestinal tissue isolated from the sites of
PIP peptide exposure over the time course of blood sugar measurements
(Fig. 3B & C).
The ratio of total MLC to pMLC was assessed by semi-quantitative
Western blot analysis (Fig. 4A). This analysis demonstrated that the
MLC phosphorylation ratio induced by 20 mM peptide 640 wasFig. 4. Intraluminal intestinal injection of PIP peptides transiently increases pMLC content
and enhances paracellular uptake of insulin in non-diabetic rat intestinal tissue in vivo.
(A) Representative semi-quantitative Western blot analysis (at 45 min) used to assess
changes in the extent of myosin light chain (MLC) phosphorylated at Ser19 (pMLC-
Ser19) relative to total MLC content. (B) ILI injection of PIP peptides increases pMLC
content. Ratios of MLC to pMLC-Ser19 levels in rat intestinal tissue at selected time points
following apical application of PIP peptides at designated concentrations. * p b 0.05.
(C) Paracellular transport of ﬂuorescent (Cy3-labeled) insulin enhanced by PIP peptides
following ILI injection. Nuclei are DAPI-stained (blue). Black arrows show label at luminal
surface; white arrows show label penetrating between adjacent epithelial cells. Bar =
10 μm.
Fig. 5. PIP peptides 250 and 640 enhance the uptake of human insulinwith different kinet-
ics from the intestinal lumen of non-diabetic rats. (A) Time-concentration proﬁles of insu-
lin in serumsamples fromblood collected from theportal vein following ILI injection of PIP
peptideswith 30 IU/kg of insulin. One-wayANOVA shows data sets are signiﬁcantly differ-
ent from each other (p b 0.01). Bonferroni post-tests show that insulin with peptide 250
(p b 0.01) and insulinwith peptide 640 (p b 0.05) were signiﬁcantly different from insulin
only. (B) Time-concentration proﬁles of insulin in serum samples collected from the tail
vein following ILI injection of PIP peptides with 30 IU/kg of insulin. There was no signiﬁ-
cant difference between the groupswhen compared using onewayANOVA (C) Time-con-
centration proﬁles of insulin in in serum samples of blood collected from the tail and portal
veins of non-diabetic mice following a SC injection of 3 IU/kg of human insulin. Data are
means ± SD for n = 3 for each treatment group.
194 A. Taverner et al. / Journal of Controlled Release 210 (2015) 189–197signiﬁcantly increased by 15 min and remained elevated at 45 min be-
fore returning to initial levels at 90 min. The MLC to pMLC ratio proﬁle
achieved with 20 mM peptide 250 showed no signiﬁcant changes at
15 min but was elevated at 45 min before returning to basal levels at
90 min (Fig. 4B). These results correlated well with the time course of
blood sugar depression induced by the co-administration of these PIP
peptides with insulin (Fig. 3B & C). It is important to note that, while
care was taken to isolate MLC from only the intestinal epithelial cells,
the extraction procedure used could have resulted in someMLC isolated
from other cells present in these isolated intestinal tissues.
We probed our hypothesis of the PIP peptide mechanism of action
further by examining the fate of a ﬂuorescent-labeled form of insulin
following its ILI injection. Fluorescent (Cy3-labeled) insulin was ob-
served in the intestinal paracellular space only when co-administered
with a PIP peptide without gross anatomical modiﬁcation of the epithe-
lium(Fig. 4C). Together, these results support thehypothesis that apical,
topical application of PIP peptides act locally to increase paracellular
permeability of rat intestinal epithelium in vivo. Further, the time
course of increase paracellular permeability of insulin was consistent
with the role of a transient increase of pMLC content in epithelial cells.
3.5. Fate of PIP peptide enhanced uptake of insulin
Time course studies monitoring blood glucose depression and alter-
ations inMLCphosphorylation relevant to totalMLC cell content follow-
ing ILI injection of PIP peptides and 30 IU of insulin suggest an in vivo
event window of approximately 30–60 min. To explore this further,
we measured serum insulin concentrations in blood collected from
the portal vein (Fig. 5A) and the tail vein (Fig. 5B) from 5 to 90 min fol-
lowing ILI injection. Onset of measurable insulin levels and their con-
centration in the portal vein suggested peptide 640 to incite a more
rapid onset of action and shorter duration of action compared to peptide
250, consistent with the time course for phosphorylation ratio changes
for these two peptides (Fig. 4).
The total amount of insulin detected by ELISA in the portal and
systemic (tail vein) after ILI of 30 IU/kg showed slightly different proﬁles
following enhanced uptake by peptide 250 versus peptide 640 for the
conditions tested here. Additionally, we determined time-concentration
proﬁles for portal and systemic concentrations of insulin following SC in-
jection (Fig. 5C). Using non-compartmental analysis, the relative bioavail-
ability of oral administration (relative to SC) for human insulin detected
in the portal veinwhen administered by ILI with peptide 250 versus pep-
tide 640 were 4% and 3%, respectively. Interestingly, the relative
bioavailabilies for human insulin reaching the systemic circulation fol-
lowing ILI administration with peptide 250 versus peptide 640 was
1.6% and 1.4%, respectively. These results suggested that a substantial
fraction of human insulin delivered to the portal vein did not reach the
systemic circulation.
3.6. Epithelial cell viability following PIP peptide exposure
Initial in vitro studies using Caco-2 cells suggested that peptide 250
and 640, tested at concentrations that modulated TEER and paracellular
permeability, did not affect cell viability as assessed by themitochondri-
al membrane polarity marker MTS (data not shown). Due to the
transient nature of PIP actions in vivo, we focused on cell signals that
might better deﬁne early cellular changes that could correlate with
decreased cell viability; activation of the caspase enzyme cascade is an
early step in apoptosis events in epithelial cells [25]. We measured the
level of caspase-3 activity in rat intestinal tissue isolated 45 min after
apical exposure of peptides 250 or 640 at concentrations shown to
decrease blood glucose (Fig. 3), increase the extent of pMLC (Fig. 4),
and enhance the uptake of insulin into the portal vein (Fig. 5). Intestinal
tissues failed to show an induction of caspase-3 enzyme activity follow-
ing similar apical exposure of 20 mM PIP peptide 250 or 640, while
hygromycin (150 μg/mL) administered by ILI was used as a positivecontrol for the induction of caspase-3 did result in increasing this en-
zyme activity (Fig. 6). The concentration of endotoxin in portal vein
blood was measured following injection of 20 mM PIP peptide 250 or
640 with insulin or insulin alone. No difference was observed between
the treatments (data not shown).
4. Discussion
A wide variety of agents have been tested in an effort to increase in-
testinal paracellular ﬂux for the purposes of enhancing the oral delivery
of biopharmaceuticalswith quillaja saponin, dipotassium glycyrrhizinate,
Fig. 6. PIP peptides 250 and 640 enhance the uptake of human insulin from the intestinal
lumen of non-diabetic rats without induction of apoptosis pathway activation. Caspase-3
enzyme activity in intestinal tissues isolated 45min after ILI injection of PIP peptides at the
designated concentration. Hygromycin (150 μg/mL) was administered by ILI injection to
serve as a positive control for the induction of caspase-3. Data are means ± SD for n =
3 for each treatment group * p b 0.05.
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just a few of the agents that have been described [31–33]. In general,
these agents were selected empirically through screens involving
in vitro cell systems such as Caco-2 monolayers or isolated intestinal
tissues [6]. Some of these agents, like palmitoyl carnitine, initially showed
promise but ultimately their beneﬁtswere correlatedwith lytic effects on
cell membranes that reduced cell viability [32]. Sodium caprate, a
medium chain fatty acid present in human milk and approved as an
absorption-enhancing agent in a rectal ampicillin suppository causes TJ
dilations andenhancesparacellular permeability in vitro [34]; the efﬁcacy
of caprate in vivo in man, however, is better correlated with non-speciﬁc
damage to the rectal mucosa rather than paracellular permeability
modiﬁcation [35].
Toxicity, primarily based upon an uncertainty of a speciﬁc mecha-
nism of action (or actions), seems to be a central element that limits
the identiﬁcation of agents to safely enhance paracellular transport for
the oral delivery of biopharmaceuticals. It appears that transient chang-
es in cellular elements involved in controlling TJ function are not overly
toxic. For example, themediumchain fatty acid caprate has been shown
to alter expression of the TJ component tricellulin, presumably increas-
ing paracellular ﬂux through disrupted tri-cellular contracts in the
epithelium [33]. Further, a novel oily suspension of medium chain
fatty acid salts that transiently altered the intracellular distribution of
zonula occludens-1, a component of functional TJs, to promote absorp-
tion by increasing paracellular permeability of the intestinal epithelium
has been shown to be safe in monkey toxicity studies [36]. This concept
of enhancing paracellular permeability through manipulation of TJ
protein function and/or organization correlates well with in vitro and
in vivo data showing that a peptide emulating an extracellular loop
domain of the TJ protein claudin 1 can similarly enhance paracellular
ﬂux [37]. Therefore, methods to selectively and transiently disorganize
TJ contacts may provide a potential mechanism of action to effectively
increase paracellular permeability.
We have used two rationally designed agents to incite a deﬁned
mechanism of action that leads to the transient opening of intestinal
TJs. Our approach is based upon landmark ﬁndings made initially by
Papenheimer and co-workers that demonstrated the intestinalepithelium to have an endogenous nutrient-activated mechanism for
the transient increase in paracellular permeability of solutes [10]. Sub-
sequent studies showed that this increase in paracellular permeation
was due to an increase in myosin light chain (MLC) phosphorylation
driven by Na+-dependent nutrient uptake processes [38]. Validation
of MLC phosphorylation in controlling TJ-mediated solute permeability
was initially validated using a rationally designed, stable, membrane
permeable inhibitor of MLC kinase (PIK) peptide that was shown to be
effective in models of chronic epithelial inﬂammation where unabated
MLC kinase (MLCK) activity maintains the epithelia in a hyper-
permeable state characterized by increased pMLC levels [12,39]. Pres-
ently, we identiﬁed similar membrane-permeable, stable, selective in-
hibitors of MLC phosphatase (MLCP) that counterbalances the actions
of residualMLCK activity (Fig. 7A and B). Our rationalewas that the top-
ical application of such peptides in vivo would result in a local action on
TJ function and that this action would be transient due to dilution and
elimination following local action onMLCP activity (Fig. 7C). The cumu-
lative in vitro and in vivo data present in this report is consistent with
that concept.
We used information from published crystal structures to design
short peptide sequences capable of selectivelymodulating protein–pro-
tein interactions with the goal of emulating interfacial contacts involv-
ing MLCP regulatory proteins: CPI-17 and MYPT [16,40]. Investigations
over the last 20 years have demonstrated Ca2+/calmodulin to activate
MLCK activity while Rho kinase and protein kinase C (PKC) regulate
MLCP through MYPT1 and CPI-17, respectively [41]. Additional studies
have described the impact of Rho kinase and PKC-zeta on intestinal TJ
function [42]. Our design of PIP peptides 250 and 640 addressed several
issues associated with using small peptides to target an intracellular
protein–protein contact site: peptides that have extensive interfacial
contact sites sufﬁcient to achieve target speciﬁcity can suffer from
poor membrane permeability and are further limited by peptidase-
mediated catabolism in the intestinal lumen and epithelial cell cyto-
plasm [13]. To overcome these issues, we selected protein–protein in-
terfaces that could accommodate peptides prepared from all D-amino
acids for increased stability and that would contain an increased posi-
tive/negative charge ratio to increase membrane permeability.
Recent studies have validated the approach of using stable, mem-
brane permeable peptides to disrupt an interfacial contact site and alter
protein phosphatase 1 in living cells [43]. As previously shown for
MLPC modulation with a membrane-permeant peptide designed to tar-
get the RVxF-type PP1-binding motif [43] and other cell membrane pen-
etrating peptides [7,44], the PIP peptides examined in our studies did not
show signiﬁcant cytotoxic actions. This is in striking contrast to
microcystins, a class of cyclic heptapeptide hepatoxins that inhibit PP1
alongwith othermultiple other Ser/Thr protein phosphatases by binding
to a site common to all [45]; illnesses associated with microcystin intox-
ication are related to non-speciﬁc actions resulting from increased phos-
phorylation of many proteins [46]. While the PIP peptides 640 and 250
are effective and non-toxic, the concentrations required for their function
are in the millimolar range with the PIP peptide: insulin ratio being
~0.96:0.04. This does not appear to be a strategy-limiting issue since
achieving these soluble concentrations of these peptides at local, topical
applications where a biopharmaceutical is positioned simultaneously is
readily achieved and are in the concentration range currently being
employed for empirically derived permeation enhancers. Further, no
optimization efforts have yet been performed for these PIP peptides.
We have characterized the extent of insulin that could be
transported across the rat intestinal epithelium as a consequence of
transiently opening the paracellular route between adjacent epithelial
cells. Our studies showed that less than 5% of the material placed in
the intestinal lumen could be absorbed. While the peptides used to
increase the paracellular permeability were designed to be stable in
the enzymatically active environment of the small intestine, the insulin
that was co-administeredwould have beenmuchmore labile. Formula-
tion or chemical modiﬁcation strategies to improve the stability of a co-
Fig. 7. Conceptual aspects of the PIP peptides strategy. (A) General relationship between TJ barrier function andMLC phosphorylation status. (B) Schematic representation ofmechanisms
regulating the activity of MLC kinase and MLC phosphatase. Ca2+/calmodulin-mediated activation of MLC kinase (MLCK) causes contraction of the actomyosin cytoskeleton associated
with TJ structures, resulting in dilation of the space between adjacent epithelial cells–enhanced paracellular permeability. The PIP (permeant inhibitor of phosphatase) peptides (green
arrows) described in these studies were designed to disrupt MYPT1 or CPI-17 regulation of MLCP function. PIK (permeant inhibitor of kinase) action on MLCK is noted by a red arrow.
(C) Cartoon depicting several of the dynamic factors affecting the PIP peptide-mediated enhancement of insulin uptake. PIP peptide (purple star) entry into epithelial cell andmodulation
ofMLCP function at the TJ to open the paracellular route to solutes, a transient effect due to the systemic uptake, dilution, and elimination. Co-administration of insulin (yellow circles)with
a PIP peptide facilitates uptake of this hormone into the portal vein. The location and duration of insulin uptake is dependent upon sufﬁcient adjacent PIP concentration and actions.Move-
ment along the intestinal lumen over time (arrows) and dilution into the luminal contents should affect both PIP peptide actions and the extent of insulin uptake.
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outcome during the brief period of action of these PIP peptides.
Although increasing the duration and extent of TJ opening using these
PIP peptides should also improve this bioavailability outcome, we
would be cautious about this strategy from a safety perspective. Inter-
estingly, delivery of a biopharmaceutical, such as insulin, by this route
may have added physiological beneﬁt that could compensate for this
low bioavailability issue. We observed that approximately half of the
absorbed dose present in the portal vein reached the systemic circula-
tion. Such an outcome is consistent with the more physiologically-
relevant and previously established insulin-based regulation of glucose
levels resulting from pancreatic secretion [47,48].
Overall, our studies have identiﬁed a novel strategy to dynamically
regulate an endogenous mechanism that controls paracellular perme-
ability in the intestine epithelium and identiﬁed two rationally designedPIP peptides: 250 and 640. The 640 peptide was designed to affect a
PKC-mediated regulator of MLCP and peptide 250 was designed to
affect a Rho-kinase-mediated regulation of MLCP. Interestingly, re-
sponses induced by peptide 250 appear to be less dynamic than those
affected by peptide 640. The actions of these peptides, however, should
be dependent upon a variety of factors that might be different for the
two peptides: rate of cell entry, residence time in the cell, and afﬁnity
for the intracellular target. Assuming that the potential differences
were not overwhelming at the concentrations of PIP peptides used in
these studies, our data is consistentwith the concept that Rho A activity
may mediate slower, more durable TJ changes through its actions on
MYPT1 while PKC actions on CPI-17 may provide a mechanism for
more rapid and dynamic changes in TJ function for intestinal epithelia
function. Further studies, however, will be required to fully test this
hypothesis and its potential clinical applications.
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